Table summarising the indicators that are grouped in the priority area of ‘anticoagulants in atrial fibrillation’; including whether they apply to primary or secondary care, the units being used to measure each, and what the overall target is for GP practices and health boards in NHS Wales for 2021 to 2022

| **National Prescribing Indicator** | **Applicable to:** | **Unit of measure** | **Target for 2021–2022** |
| --- | --- | --- | --- |
| **Priority area** |
| **Anticoagulants in atrial fibrillation**  | Primary care | The number of patients with AF and a CHA2DS2-VASC score of 2 or more who are currently prescribed an anticoagulant, as a percentage of all patients with AF. | To increase the number of patients with AF and a CHA2DS2-VASC score of 2 or more prescribed an anticoagulant. |
| The number of patients diagnosed with AF who are prescribed an anticoagulant and have received an anticoagulant review within the last 12 months, as a percentage of all patients diagnosed with AF who are prescribed an anticoagulant. | To increase the number of patients who are prescribed an anticoagulant and have received an anticoagulant review within the last 12 months. |
| The number of patients diagnosed with AF who are prescribed antiplatelet monotherapy, as a percentage of all patients diagnosed with AF. | To reduce the number of patients with AF prescribed antiplatelet monotherapy. |